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a role in the formation of
anti-PF4/H antibodies.
Introduction
Heparin-induced thrombocytopenia (HIT) is a life-threatening complication of heparin exposure with
estimated incidences of 1 in 5000 in general inpatients and 1% to 2% in inpatients following cardiac
surgery.1,2 Antibodies against platelet factor 4 (PF4)/heparin (PF4/H) complexes trigger platelet
activation, leading to consumptive thrombocytopenia and acquired thrombophilia capable of
precipitating severe venous and arterial thrombosis.3 Enzyme-linked immunosorbent assays (ELISAs)
are commonly performed to measure anti-PF4/H antibodies in patients with suspected HIT. High optical
density (OD) values by ELISA correlate with increased platelet activation in serotonin release assays,4,5
and with the presence of clinical HIT.6-9
The mechanism for developing an anti-PF4/H response is poorly understood, as neither heparin nor PF4
is a foreign antigen in humans. Exogenous heparin may alter intracellular PF4 processing within antigen-
presenting cells, causing presentation of aberrant PF4-derived peptides (neoantigens) to T cells.10,11
Although T cells are necessary for the development of anti-PF4/H in murine models,12 proof for aberrant
antigen presentation is lacking.
Human PF4 neoantigen presentation may be restricted to specific HLA molecules. We
hypothesized that patients having certain class II HLA alleles are predisposed to increased anti-
PF4/H antibodies after exposure to heparin. Here, we present a cohort study of 412 heparin-
exposed inpatients with paired anti-PF4/H and high-resolution HLA-typing results. We found that




We conducted a single-center cohort study of inpatients who received IV unfractionated heparin for
anticoagulation and were subsequently tested for anti-PF4/H due to concerns for HIT (Figure 1). Eligible
patients were identified and their demographic information collected from the electronic medical record
system. Anti-PF4/H in peripheral blood was measured using a commercial, poly-specific enzyme
immunoassay (Asserachrom HPIA-ELISA; Diagnostic Stago). DNA was extracted from residual blood
specimens and sequenced (Illumina) for high-resolution 2-field typing of the HLA-DRB1 and -DQB1
loci.13,14 Study approval was obtained from the Human Research Protection Office of Washington
University in St. Louis.
Data analysis
HLA genotypes were examined at both the allele and the amino acid residue levels. Alleles exceeding
5% frequency in our study population were analyzed. Significance for differences in OD values between
groups was evaluated using the Welch 2-sided unequal variances Student t test. Significance for
associations between OD values (categorized as either high or low based on a moving OD cutoff) and
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    HLA amino acid absent vs present (Fig. 2B top row)
2. Association (Chi-squared test)
    HLA allele vs OD (Fig. 2A bottom row)
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either allele or amino acid residue (categorized as present or
absent) was evaluated using the x2 test of independence. The false




Between September 2016 and November 2017, 437 patients were
evaluated, of whom 420 with blood specimens available were
enrolled. The final analysis included 412 patients (176 females
[42.7%]) who were successfully typed at both HLA loci (Figure 1A).
Our study population contained 337 white, 73 black, and 2 Asian
patients. Ages ranged from 21 to 87 years (median, 62 years;
interquartile range, 50-69 years). Antibody OD values ranged from
0.01 to 3.00 (median, 0.20; interquartile range, 0.09-0.53). There
was no significant difference in OD values between patients based
on sex, race, or age. Altogether, 43 DRB1 and 18 DQB1 alleles
exceeded 5% frequency in our study population (Figure 1B).
Genetic linkage was evident between several DRB1-DQB1 allele
pairs (Figure 1C).
Anti-PF4/H vs HLA allele
Patients with the DRB1*03:01 and/or DQB1*02:01 allele(s) had
higher OD values than those without (P5 .004-.007; Figure 2A top
row), even after controlling for sex, race, and age. Using a moving
OD cutoff to classify anti-PF4/H levels as either high or low, the
presence of these alleles was associated with high anti-PF4/H over
a broad range of OD value cutoffs (Figure 2A middle and bottom
rows). Notably, patients possessing both DRB1*03:01 and
DQB1*02:01 had 4 times the odds of other patients of having an
OD value exceeding 1.5. Patients having both alleles constituted
44.7% of all patients whose OD values exceeded 1.5 (17 of 38); the
baseline frequency for having both alleles was 22.3% (92 of 412).
Anti-PF4/H vs HLA amino acid residue
The top amino acid residue candidates for driving increased anti-
PF4/H were R74, N77, and Y26, all within the peptide-binding
groove of DRB1 (Figure 2B-C). Patients having these residues had
higher OD values than those who did not (P5 .015-.027; Figure 2B
top row). These patients had 3 times the odds of other patients of
having an OD value exceeding 1.5 (Figure 2B middle and bottom
rows). Patients having all 3 residues constituted 47.4% of all
patients whose OD values exceeded 1.5 (18 of 38); the baseline
frequency was 26.4% (109 of 412).
Discussion
We investigated immunogenetic risk for elevated anti-PF4/H,
which ultimately causes clinical HIT in a subset of patients, by the
hypothesis that HLA-restricted aberrant antigen presentation
precedes production of anti-PF4/H. Our end point was ELISA
anti-PF4/H level. Other end points such as serotonin release
assay or clinical HIT with thrombosis, despite their importance,
require additional elements (eg, platelet-related factors) to
manifest. Due to a lack of uniformly accepted OD value cutoff
for positivity,15 we characterized the complete OD value
distribution and examined all possible cutoffs. We found that
DRB1*03:01 and DQB1*02:01 were significant risk factors for
increased anti-PF4/H antibodies following heparin exposure
among inpatients.
Earlier studies generated inconsistent findings of association
between HLA and anti-PF4/H.16-18 These studies were limited by
the typing methodology at the time, providing low-resolution16,17 or
inferred18 typing only. One study also used healthy individuals
without known heparin exposure as controls.16 Our results
corroborate the finding of DR3-HIT antibody association from
Paparella et al,17 extending their conclusions from cardiovascu-
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C
Figure 1. Study overview. (A) Study design. (B) Frequency of study patients by their HLA-DRB1 and -DQB1 alleles, with alleles ordered from most to least frequent. (C)
Heat map of genetic linkage detected between HLA-DRB1 and -DQB1 alleles. Intensity (overlap) equals the number of patients having both DRB1 and DQB1 alleles divided
by the number of patients having at least 1 of the alleles.
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used high-resolution HLA typing to enable prediction of risk-
carrying residues within the peptide-binding groove of DRB1,
providing a basis for future investigations into which peptides may
cause disease.
The DRB1*03:01-DQB1*02:01 haplotype has been associated
with multiple autoimmune disorders, including celiac disease,19
type 1 diabetes,20 and systemic lupus erythematosus.21 HIT may
share similar pathogenesis with these disorders via aberrant antigen
presentation by DRB1*03:01 and/or DQB1*02:01. One of the
DRB1 amino acid residues associated with increased anti-PF4/H
(Y26) has been implicated in type 1 diabetes and autoimmune
thyroid disease.22 In patients with celiac disease, altered gut
microbiota23 or defective intestinal barriers may also prime an
anti-PF4/H response given the observed connection between
bacteria and HIT antibodies.24 Presence of a shared suscepti-
bility to these autoimmune disorders and elevated anti-PF4/H
antibodies could signal an increased pretest probability for HIT in
thrombocytopenic heparin-exposed patients having a known history
of autoimmunity.
Our study is limited by sampling from a single institution without
a replication cohort. Dosages, durations, and indications for
heparin, as well as patient histories including the presence of
autoimmune disease, could not be reliably ascertained for the study.
We also examined only DRB1 and DQB1 in order to balance
investigating the most functionally relevant class II loci with
minimizing redundant or multiple testing (for example, DRB3/4/5
were omitted due to well-established tight genetic linkage with
DRB1-DQB1), and therefore cannot rule out the contribution
of other HLA loci or other genetically linked genes in the HLA
region that may affect anti-PF4/H production. Finally, an
immunoglobulin G–specific ELISA may have been better suited
for this study compared with the poly-specific assay available at
our institution, although high values from either assay correlate
























































































































































Figure 2. Association between HLA and anti-PF4/H antibody levels. (A) HLA allele associations: top row, distribution of OD values; middle row, odds ratio for having an
OD value above vs below a given cutoff; and bottom row, significance of association across all possible cutoffs (95% confidence intervals in pink). (B) HLA amino acid residue
associations: top row, distribution of OD values; middle row, odds ratio for having an OD value above vs below a given cutoff; and bottom row, significance of association
across all possible cutoffs (95% confidence intervals in pink). (C) Two views of candidate amino acid residues within DRB1 driving risk for anti-PF4/H antibody development
(Protein Data Bank code: 1A6A). *Significance within a 5% false discovery rate.























































































































































































SIDE VIEW Top-DOWN VIEW
Figure 2. (Continued).
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to further understand the functional relationship between HLA
and anti-PF4/H antibodies.
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